




CHUGAI PHARMACEUTICAL CO., LTD.

 A member of the Roche group

CONSOLIDATED FINANCIAL STATEMENTS (Japan GAAP) (Non-audited) (through the third quarter of fiscal year 2011)

Name of Company: **Chugai Pharmaceutical Co., Ltd.** October 21, 2011
 Stock Listing: Tokyo Stock Exchange, First Section
 Security Code No.: 4519 (URL <http://www.chugai-pharm.co.jp/english>)
 Representative: Mr. Osamu Nagayama, President and CEO, Chairman of the Board of Directors
 Contact: Mr. Nobuyuki Chiba, General Manager of Corporate Communications Department
 Phone: +81-(0) 3-3273-0881
 Date of Submission of Marketable Securities Filings: November 7, 2011
 Date on which Dividend Payments to Commence: —
 Supplementary Materials Prepared for the Quarterly Financial Statements: Yes
 Presentation Held to Explain the Quarterly Financial Statements: Yes (for institutional investors, analysts)

1. Consolidated Operating Results through the Third Quarter of FY 2011 (January 1, 2011–September 30, 2011)

(1) Consolidated Operating Results (cumulative)

Note: Amounts of less than one million yen are omitted.

	Revenues	% change	Operating Income	% change	Ordinary Income	% change
First nine months of FY 2011	¥276,018 million	(0.0)	¥50,013 million	10.8	¥51,059 million	15.4
First nine months of FY 2010	¥276,076 million	(10.9)	¥45,129 million	(23.2)	¥44,258 million	(33.0)

	Net Income	% change	Net Income per Share (Basic)	Net Income per Share (Fully Diluted)
First nine months of FY 2011	¥27,129 million	(3.3)	¥49.85	¥49.84
First nine months of FY 2010	¥28,053 million	(31.4)	¥51.55	¥51.54

Note: Percentages represent changes compared with the same period of the previous fiscal year.

(2) Consolidated Financial Condition

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
As of Sep. 30, 2011	¥534,420 million	¥451,649 million	84.2%	¥826.39
As of Dec. 31, 2010	¥508,016 million	¥449,394 million	88.0%	¥821.87

Reference: Shareholders' equity at Sep. 30, 2011: ¥449,716 million

Shareholders' equity at Dec. 31, 2010: ¥447,256 million

2. Dividends

	Annual Dividends				
	End of First Quarter	End of Second Quarter	End of Third Quarter	End of Fiscal Year	Total
FY ended Dec. 2010	—	¥17.00	—	¥23.00	¥40.00
FY ending Dec. 2011	—	¥20.00	—		
FY ending Dec. 2011 (Forecast)			—	¥20.00	¥40.00

Note: Whether the dividend forecast under review has been revised: No

3. Forecast of Consolidated Results for FY 2011 (January 1, 2011–December 31, 2011)

	Revenues	% Change	Operating Income	% Change	Ordinary Income	% Change
FY 2011	¥395,200 million	4.1	¥72,000 million	8.7	¥73,100 million	12.3

	Net Income	% Change	Net Income per Share (Basic)
FY 2011	¥37,000 million	(10.7)	¥67.99

Notes: 1. % change figures for revenues, operating income, ordinary income, and net income are presented in comparison with the same period of the previous fiscal year.
2. Whether the forecasts for consolidated figures under review have been revised: No

4. Others (For details, see the “Other Information” section on page 4.)

(1) Changes in the state of material subsidiaries during the period: None

Note: Changes in the state of specific subsidiaries during the period attendant with change in scope of consolidation

(2) Application of simplified accounting methods and/or special accounting method: Yes

Note: Application of simplified accounting methods and/or special accounting methods for preparation of the quarterly consolidated financial statements

(3) Changes in principles, procedures, methods of presentation, etc.

(a) Changes accompanying revisions in accounting principles: Yes

(b) Changes other than those in (a) above: None

Note: Changes in principles, procedures, methods of presentation, etc., related to “changes in material items that form the basis for the preparation and presentation of the quarterly consolidated financial statements”

(4) Number of shares issued (common stock):

(a) Number of shares at the end of the period (including treasury stock)

(b) Number of treasury stock at the end of the period

(c) Average number of shares issued during the period (nine months)

Third quarter of FY 2011	559,685,889 shares	FY 2010	559,685,889 shares
Third quarter of FY 2011	15,493,766 shares	FY 2010	15,491,466 shares
Third quarter of FY 2011	544,193,511 shares	Third quarter of FY 2010	544,193,553 shares

Note: Items related to the status of the implementation of quarterly reviews

At the time of disclosure of these quarterly consolidated financial statements, review procedures were in progress for the quarterly financial statements based on the Financial Instruments and Exchange Act.

Note: Explanation of the appropriate use of performance forecasts and other related items

Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual financial results may materially differ from these forecasts due to potential risks and uncertainties.

For the specifics of the above forecasts, please refer to the item “(3) Qualitative Information Regarding the Forecast for Consolidated Performance” in the “Qualitative Information” section of on page 4.

Index of the Attachment

1. Qualitative Information	2
(1) Qualitative Information Regarding Operating Results (Consolidated)	2
(2) Qualitative Information Regarding Financial Condition (Consolidated)	3
(3) Qualitative Information Regarding the Forecast for Consolidated Performance	4
2. Other Information	4
(1) Summary of Changes in the State of Material Subsidiaries	4
(2) Summary of Application of Simplified Accounting Methods and/or Special Accounting Method	4
(3) Summary of Changes in Principles, Procedures, Methods of Preparation, etc.	5
3. Consolidated Financial Statements	6
(1) Consolidated Balance Sheets	6
(2) Consolidated Statements of Income	8
(3) Consolidated Statements of Cash Flows	9
(4) Notes Regarding Assumptions as a Going Concern	10
(5) Segment Information	10
(6) Notes Regarding Major Changes in Shareholders' Equity	10

Note: The Company is scheduled to hold a conference call for investors as noted below. The materials used for the call, the voice portion, the Q&A, and other related documents will be posted on the Company's website immediately following the conclusion of the conference call.

Teleconference for institutional investors and analysts: October 21, 2011, Friday (Japan time)

1. Qualitative Information

(1) Qualitative Information Regarding Operating Results (Consolidated)

(Billions of Yen)

	First nine months of FY 2010.12 (Jan. 1, 2010–Sep. 30, 2010)	First nine months of FY 2011.12 (Jan. 1, 2011–Sep. 30, 2011)	% Change
Revenues	276.1	276.0	(0.0)
Sales (excluding Tamiflu)	257.4	261.2	+1.5
Cost of sales	119.6	115.4	(3.5)
Gross profit	156.5	160.7	+2.7
SG&A (excl. R&D) expenses	71.4	69.4	(2.8)
R&D expenses	39.9	41.2	+3.3
Operating income	45.1	50.0	+10.9
Ordinary income	44.3	51.1	+15.3
Net income	28.1	27.1	(3.6)

Consolidated revenues through the third quarter under review were ¥276.0 billion (a decrease of 0.0% year on year).

Sales of the anti-influenza agent Tamiflu, which vary widely from year to year, amounted to ¥6.3 billion (a decline of 60.1% year on year). After the exclusion of sales of Tamiflu and other operating revenues, which amounted to ¥8.5 billion (representing a 203.6% increase year on year), sales amounted to ¥261.2 billion (an increase of 1.5% year on year), as growth in overseas sales absorbed the decline in domestic sales caused by the constraints on marketing activities owing to the effects of the Great East Japan Earthquake, adjustments in shipments, and other factors.

Domestic Sales (Excluding Tamiflu)

As a result of the Great East Japan Earthquake, which occurred on March 11, 2011, the Utsunomiya plant of Chugai Pharmaceutical Manufacturing Co., Ltd., and plants of certain contract manufacturers were damaged, and shipment adjustments are still being made for a portion of the Company's products. Owing to the prolongation of constraints on marketing activities because of difficulties in fully coping with the direct and indirect effects of the earthquake, domestic sales, excluding Tamiflu, amounted to ¥227.8 billion (a decrease of 1.5% year on year).

In the oncology field, although sales amounted to ¥101.5 billion (an increase of 1.4% year on year), the rate of growth declined. This was due to a slowdown in expansion of sales of Avastin (an anti-vascular endothelial growth factor (VEGF) receptor humanized monoclonal antibody, anti-cancer agent), which previously had expanded following the approval for an additional indication of non-small cell lung cancer in November 2009, and the decline in sales of Kytril (a 5-HT₃ receptor antagonist, antiemetic agent) owing to the effects of the emergence of many generic products.

In the bone and joint disease field, sales amounted to ¥47.2 billion through the third quarter under review (an increase of 7.0% year on year), thus remaining on an upward trend. This increase was driven by expansion in sales of Actemra (a humanized anti-human IL-6 receptor monoclonal antibody), which received an additional indication in April 2008 for the treatment of rheumatoid arthritis. In addition, sales of Ediroi (an active vitamin D₃ derivative) which was launched in April 2011, contributed to the rise in sales, although market penetration has been slower than initially expected.

In the renal diseases field, sales amounted to ¥36.9 billion (a decline of 11.5% year on year). Although Mircera (a long-acting erythropoiesis stimulating agent) was launched in July 2011, market penetration did not proceed as initially planned. In addition, sales of Epogin (a recombinant human erythropoietin) declined largely because of the effects of increased competition and the shift to usage of Mircera.

In the transplant, immunology, and infectious disease fields (excluding Tamiflu), sales were ¥17.0 billion (a decline of 7.1% year on year), as sales of Pegasys (a peginterferon-a-2a) and Copegus (an anti-viral agent) declined owing to the continuing effect of the shrinkage in the market for the treatment of chronic hepatitis C.

Tamiflu (an Anti-influenza Agent)

Sales of Tamiflu for ordinary use through the third quarter amounted to ¥4.1 billion (an increase of 192.9% year on year). Sales to government stockpiles through the third quarter amounted to ¥2.2 billion (a decline of 84.7%).

Overseas Sales

Overseas sales were ¥33.4 billion (an increase of 28.0% year on year). Although sales of Neutrogin (a recombinant human granulocyte-colony stimulating factor (G-CSF)) decreased because of the effects of competition from follow-on biologics and currency fluctuations, exports of Actemra to F. Hoffman-La Roche Ltd. increased.

Profit (Loss) Condition

Gross profit through the third quarter amounted to ¥160.7 billion (an increase of 2.7%). This increase was due to a major rise in other operating revenues that accompanied a lump-sum payment received along with the out-licensing of GC33, an increase in revenues related to Actemra, and other factors.

Selling, general and administrative expenses, excluding R&D expenses, were ¥69.4 billion (a decrease of 2.8% year on year), owing to the constraints on marketing activities that emerged following the Great East Japan Earthquake. R&D expenses were ¥41.2 billion (an increase of 3.3% year on year), reflecting progress on development themes.

As a result, operating income amounted to ¥50.0 billion (an increase of 10.9% year on year), and ordinary income was ¥51.1 billion (an increase of 15.3% year on year). Net income through the third quarter amounted to ¥27.1 billion (a decrease of 3.6% year on year). This figure reflects the reporting of extraordinary losses of ¥9.1 billion due to losses in connection with the Great East Japan Earthquake and the application of Accounting Standards for Asset Retirement Obligations.

Note: In this item, amounts less than ¥100 million have been rounded off. Figures for changes in amounts and percentage increases and decreases have been calculated using data denominated in ¥100 million units.

(2) Qualitative Information Regarding Financial Condition (Consolidated)**Assets, Liabilities, and Net Assets**

At the end of the third quarter under review, total assets on a consolidated basis amounted to ¥534.4 billion, representing an increase of ¥26.4 billion in comparison with the end of the previous fiscal year. This gain was mainly the net result of a rise in cash and deposits of ¥34.5 billion, a decrease in trade notes and accounts receivable of ¥15.0 billion, and an increase in raw materials and supplies of ¥9.6 billion.

Total liabilities on a consolidated basis stood at ¥82.8 billion, representing an increase of ¥24.2 billion compared with the end of the previous fiscal year. Principal factors accounting for this increase were a gain in trade notes and accounts payable of ¥9.7 billion, an increase in income taxes payable of ¥6.0 billion, and an increase in reserve for bonuses to employees of ¥4.9 billion.

Total net assets on a consolidated basis were ¥451.6 billion, representing an increase of ¥2.2 billion compared with the end of the previous fiscal year. Principal factors accounting for this rise were an increase in retained earnings of ¥3.8 billion due to the reporting of ¥27.1 billion in net income through the third quarter, which was partially offset by the payment of dividends from retained earnings of ¥23.4 billion, and a decline in foreign currency translation adjustments of ¥0.9 billion.

As a result, the consolidated shareholders' equity ratio stood at 84.2%, compared with 88.0% at the end of the previous fiscal year.

Cash Flows

Cash and cash equivalents at the end of the third quarter under review amounted to ¥101.7 billion (versus ¥58.4 billion at the end of the same quarter of the previous fiscal year).

Net cash provided by operating activities through the third quarter amounted to ¥67.8 billion (compared with ¥4.4 billion provided by operating activities for the same period of the previous fiscal year). This was primarily due to income before income taxes and minority interests of ¥42.0 billion, a decline in notes and accounts receivable of ¥14.9 billion, an increase in inventories of ¥12.3 billion, income taxes paid of ¥12.1 billion, depreciation and amortization of ¥11.4 billion, and an increase in notes and accounts payable of ¥9.8 billion.

Net cash used in investing activities was ¥6.4 billion (compared with ¥16.2 billion used in investing activities for the same period of the previous fiscal year). Principal factors accounting for this were as follows: Purchases of noncurrent assets of ¥8.9 billion, a net inflow of ¥1.8 billion from payments into time deposits and proceeds from the withdrawal of time deposits, and a net inflow of ¥0.7 billion from the purchase of marketable securities and the proceeds from sale of marketable securities.

Net cash used in financing activities was ¥24.3 billion (compared with ¥23.1 billion used in financing activities for the same period of the previous fiscal year). This was primarily due to cash dividends paid as a year-end dividend for the previous fiscal year and the interim dividend for the current fiscal year, which totaled ¥23.1 billion.

Note: In this item, amounts less than ¥100 million have been rounded off. Figures for changes in amounts and percentage increases and decreases have been calculated using data denominated in ¥100 million units.

(3) Qualitative Information Regarding the Forecast for Consolidated Performance

The Company has not made any changes in its forecast of consolidated results for the fiscal year ending December 2011 since the announcement regarding the forecast issued on July 21, 2011.

2. Other Information

(1) Summary of Changes in the State of Material Subsidiaries

None

(2) Summary of Application of Simplified Accounting Methods and/or Special Accounting Method

(a) Simplified method of accounting

(Valuation of inventories)

In calculating the amount of inventories at the end of the third consolidated quarter, the amount of inventories based on on-site inspections reported at the end of the previous consolidated fiscal year is taken as a base, and the value of inventories is determined according to reasonable methods. In addition, in calculating write-downs in the book value of inventories, only for those inventories whose profitability has clearly declined, the net sale value is estimated, and the method of reducing book value to net sales value is used.

(Method for calculating depreciation of noncurrent assets)

For assets that are depreciated using the declining-balance method, the amount of depreciation for each quarter is calculated by dividing the amount of depreciation for the consolidated fiscal year into four equal installments and charging such installments as an expense for each quarter.

(Calculation of income taxes and deferred tax assets and deferred tax liabilities)

For certain consolidated subsidiaries, the method of increasing or decreasing material calculation items and material deduction items for income tax purposes is employed in calculating the amount of income taxes payable and in calculating deferred tax assets and deferred tax liabilities.

In making judgments regarding the recoverability of deferred income tax assets, in cases where it is recognized that there have been no major changes in the management environment since the end of the previous consolidated fiscal year and no major temporary differences, the Company applies the method of using the forecast for future performance and tax planning employed at the time of the preparation of the accounts for the end of the previous consolidated fiscal year, and, in cases where it is recognized that there have been major changes in the management environment since the end of the previous consolidated fiscal year and/or major temporary differences, the Company employs the method of taking account of such changes in the forecast for future performance and tax planning.

(b) Special accounting methods for preparation of the quarterly consolidated financial statements

None

(3) Summary of Changes in Principles, Procedures, Methods of Preparation, etc.

(a) Application of “Accounting Standards for Asset Retirement Obligations”

Beginning with the first quarter of the fiscal year ending December 31, 2011, “Accounting Standards for Asset Retirement Obligations” (Accounting Standards Board of Japan (ASBJ) Statement No. 18, issued on March 31, 2008) and “Guidance on Accounting Standards for Asset Retirement Obligations” (ASBJ Guidance No. 21, issued on March 31, 2008) have been applied.

As a result, both consolidated operating income and ordinary income for the nine months through the third quarter declined ¥69 million and income before income taxes and minority interests decreased ¥1,087 million.

(b) Application of “Accounting Standards for Business Combinations and Related Matters”

Beginning with the first quarter of the fiscal year ending December 31, 2011, the Company has applied the following accounting standards. All of these accounting standards, partial amendments to existing accounting standards, and guidance were issued by ASBJ on December 26, 2008.

“Accounting Standard for Business Combinations” (ASBJ Statement No. 21)

“Accounting Standard for Consolidated Financial Statements” (ASBJ Statement No. 22)

“Partial Amendments to the Accounting Standard for Research and Development Costs” (ASBJ Statement No. 23)

“Revised Accounting Standard for Business Divestitures” (ASBJ Statement No. 7)

“Revised Accounting Standard for Equity Method of Accounting for Investments” (ASBJ Statement No. 16)

“Revised Guidance on Accounting Standard for Business Combinations and Accounting Standard for Business Divestitures” (ASBJ Guidance No. 10)

As a result, the Company made the transition from the partial mark-to-market valuation method for the assets and liabilities of its consolidated subsidiaries to the full mark-to-market valuation method. This change in valuation method had no effect on the quarterly consolidated financial statements.

3. Consolidated Financial Statements**(1) Consolidated Balance Sheets**

(Millions of Yen)

	As of September 30, 2011	As of December 31, 2010 (Summary)
Assets		
Current assets:		
Cash and deposits	110,672	76,212
Trade notes and accounts receivable	98,443	113,391
Marketable securities	58,999	59,699
Merchandise and finished goods	90,315	89,447
Work in process	368	20
Raw materials and supplies	25,049	15,417
Deferred tax assets	22,055	19,926
Other	11,824	12,427
Reserve for doubtful accounts	(4)	(5)
Total current assets	417,725	386,537
Noncurrent assets:		
Property, plant and equipment:		
Buildings and structures (net)	47,450	50,284
Other (net)	34,322	37,669
Total property, plant and equipment	81,773	87,954
Intangible assets:	2,133	2,362
Investments and other assets:		
Investment securities	6,923	7,587
Deferred tax assets	16,417	14,939
Other	9,616	8,821
Reserve for doubtful accounts	(170)	(186)
Total investments and other assets	32,787	31,161
Total noncurrent assets	116,695	121,478
Total assets	534,420	508,016

(Millions of Yen)

	As of September 30, 2011	As of December 31, 2010 (Summary)
Liabilities		
Current liabilities:		
Trade notes and accounts payable	29,205	19,489
Income taxes payable	9,653	3,679
Reserve for bonuses to employees	9,471	4,588
Other reserves	2,990	2,650
Other	26,009	24,173
Total current liabilities	77,330	54,580
Noncurrent liabilities:		
Reserves	3,397	3,325
Other	2,044	716
Total noncurrent liabilities	5,441	4,041
Total liabilities	82,771	58,621
Net assets		
Shareholders' equity:		
Common stock	72,966	72,966
Additional paid-in capital	92,815	92,815
Retained earnings	331,371	327,642
Treasury stock, at cost	(36,259)	(36,256)
Total shareholders' equity	460,893	457,167
Valuation and translation adjustments:		
Net unrealized gain on securities	1,072	1,341
Foreign currency translation adjustments	(12,249)	(11,252)
Total valuation and translation adjustments	(11,176)	(9,911)
New share warrants	949	775
Minority interests	982	1,363
Total net assets	451,649	449,394
Total liabilities and net assets	534,420	508,016

(2) Consolidated Statements of Income

(Millions of Yen)

	First nine months of FY 2010 (Jan. 1, 2010 – Sep. 30, 2010)	First nine months of FY 2011 (Jan. 1, 2011 – Sep. 30, 2011)
Revenues:		
Sales	273,252	267,470
Other operating revenues	2,823	8,548
Total revenues	276,076	276,018
Cost of sales:	119,604	115,361
Gross profit	156,472	160,657
Selling, general and administrative expenses:		
Sales promotion expenses	10,996	10,172
Salaries and allowances	20,807	20,574
Reserve for bonuses	5,513	5,836
R&D expenses	39,900	41,235
Retirement benefits	2,031	1,837
Other	32,092	30,986
Total selling, general and administrative expenses	111,342	110,644
Operating income	45,129	50,013
Non-operating income:		
Interest income	241	277
Gain on foreign exchange	1,103	1,833
Other	822	1,173
Total non-operating income	2,167	3,284
Non-operating expenses:		
Interest expenses	3	3
Loss on valuation of derivatives	2,516	1,629
Loss on retirement of noncurrent assets	100	213
Loss on abandonment of noncurrent assets	82	164
Other	336	226
Total non-operating expenses	3,038	2,237
Ordinary income	44,258	51,059
Extraordinary gain:		
Gain on sales of noncurrent assets	—	0
Gain on sales of investment securities	95	—
Subsidy	50	—
Total extraordinary gain	145	0
Extraordinary loss:		
Impairment loss	35	117
Loss on disaster	—	7,401
Restructuring loss	67	49
Loss on adjustment for changes of accounting standard for asset retirement obligations	—	1,018
Other	5	510
Total extraordinary loss	108	9,096
Income before income taxes and minority interests	44,295	41,962
Income taxes—current	17,025	17,490
Income taxes—deferred	(1,695)	(3,429)
Total income taxes	15,330	14,060
Income before minority interests	—	27,902
Minority interests in income	911	773
Net income	28,053	27,129

(3) Consolidated Statements of Cash Flows

(Millions of Yen)

	First nine months of FY 2010 (Jan. 1, 2010 – Sep. 30, 2010)	First nine months of FY 2011 (Jan. 1, 2011 – Sep. 30, 2011)
Cash flows from operating activities:		
Income before income taxes and minority interests	44,295	41,962
Depreciation and amortization	13,047	11,386
Impairment loss	35	117
Interest and dividend income	(311)	(337)
Interest expense	3	3
Loss on retirement of noncurrent assets	100	213
Loss on sales of noncurrent assets	0	0
Loss (gain) on sales and valuation of investment securities	(90)	216
Loss on disaster	—	7,401
Decrease in notes and accounts receivable	22,080	14,873
(Increase) in inventories	(23,679)	(12,308)
Increase (decrease) in notes and accounts payable	(7,901)	9,833
Other	(5,416)	7,494
Subtotal	42,163	80,856
Interest and dividends received	296	330
Interest paid	(5)	(3)
Proceeds from insurance income	—	800
Payments for loss on disaster	—	(2,053)
Income taxes paid	(38,053)	(12,081)
Net cash provided by operating activities	4,400	67,847
Cash flows from investing activities:		
Payments into time deposits	(14,387)	(9,516)
Proceeds from withdrawal of time deposits	13,398	11,296
Purchase of marketable securities	(92,386)	(83,993)
Proceeds from sales of marketable securities	85,900	84,700
Purchase of investment securities	(4)	(4)
Proceeds from sales of investment securities	1,612	—
Purchases of noncurrent assets	(10,321)	(8,861)
Proceeds from sales of noncurrent assets	0	7
Other	9	(15)
Net cash (used in) investing activities	(16,178)	(6,388)
Cash flows from financing activities:		
Net (increase) in treasury stock	(5)	(3)
Cash dividends paid	(21,769)	(23,126)
Cash dividends paid to minority interests	(1,276)	(1,125)
Other	(5)	(19)
Net cash (used in) financing activities	(23,057)	(24,274)
Effect of exchange rate changes on cash and cash equivalents	(1,221)	(660)
Net increase (decrease) in cash and cash equivalents	(36,057)	36,524
Cash and cash equivalents at beginning of year	94,478	65,143
Cash and cash equivalents at end of the period	58,420	101,667

(4) Notes Regarding Assumptions as a Going Concern

None

(5) Segment Information**Business Segments***For the first nine months of FY 2010 (Jan. 1, 2010 – Sep. 30, 2010)*

As the Company and its consolidated subsidiaries have been comprised of a single business segment, Pharmaceutical business, the disclosure of business segment information has been omitted.

Geographical Segments*For the first nine months of FY 2010 (Jan. 1, 2010 – Sep. 30, 2010)*

As revenues of the foreign consolidated subsidiaries were less than 10% of consolidated totals, the disclosure of geographical segment information has been omitted.

Overseas Revenues*For the first nine months of FY 2010 (Jan. 1, 2010 – Sep. 30, 2010)*

(Millions of Yen)

	Europe	Other Regions	Total
Overseas revenues	¥26,797	¥1,795	¥ 28,592
Revenues			276,076
% of revenues	9.7	0.7	10.4

Notes: 1. Division by country or region is based on geographical proximity.

2. The countries and regions belonging to geographical classifications are as follows:

(1) Europe: Switzerland, France, the U.K., Germany, etc.

(2) Other Regions: Republic of Korea, Taiwan, People's Republic of China, the U.S., etc.

3. Overseas revenues are defined as revenues made by the Company and its consolidated subsidiaries in countries or regions outside Japan.

Segment Information*For the first nine months of FY 2011 (Jan. 1, 2011 – Sep. 30, 2011)*

As the Company Group has been comprised of a single business segment, Pharmaceutical business, the disclosure of segment information has been omitted.

Supplementary Information

Beginning with the first quarter of the fiscal year ending December 31, 2011, "Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" (ASBJ Statement No. 17, issued on March 27, 2009) and the "Guidance on the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" (ASBJ Guidance No. 20, issued on March 21, 2008) have been applied.

(6) Notes Regarding Major Changes in Shareholders' Equity

None